Status:
UNKNOWN
Effect of Ileocolonic Delivered Vitamins and an Anti-Inflammatory Diet on Crohn's Disease and Healthy Volunteers
Lead Sponsor:
University Medical Center Groningen
Conditions:
Crohn Disease
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
This study will evaluate if the Groningen Anti-Inflammatory Diet and the ileocolonic delivery of vitamin B2, B3 and C can positively influence the course of Crohn's disease and can positively alter th...
Detailed Description
It is becoming increasingly more well known that diet and the microbiome have a pivotal role in the development and course of inflammatory bowel diseases (IBD). Strict exclusive enteral nutrition (EEN...
Eligibility Criteria
Inclusion
- Inclusion Criteria CD patients:
- Participant understands the study procedures and signed an informed consent to participate in this study
- Previously diagnosed with CD; Montreal classification: L1 (Ileal), L2 (colonic), or L3 (ileocolonic).
- Low-mild disease activity (no clinically relevant symptoms and HBI\<8 or CDAI \<220)
- Evidence of mucosal inflammation (faecal calprotectin ≥100 μg/g)
- Able to attend to the outpatient clinic of the UMCG, Martini Hospital, MCL Leeuwarden or Isala
- ≥18 years of age
- Able to use oral feeding and willing to undergo a dietary intervention (Follow a diet or use a vitamin B2/B3/C supplement or placebo)
- Inclusion Criteria healthy volunteers:
- Participant understands the study procedures and signed an informed consent to participate in this study
- Never been diagnosed with IBD or any other chronic inflammatory condition.
- Participant has no health conditions that would prevent him/her from fulfilling the study requirements as judged by the investigator on the basis of medical history and routine laboratory test results.
- Able to attend to the outpatient clinic of the UMCG, Martini Hospital, MCL Leeuwarden or Isala
- ≥18 year of age
- Able to use oral feeding and willing to undergo a dietary intervention (Follow a diet or use a vitamin B2/B3/C supplement or placebo)
- Exclusion Criteria CD patients:
- Life expectancy \<12 months
- Active Crohn's disease (HBI≥8 or CDAI\>220), or expecting drug intervention within 3 months
- Colonoscopy and colon cleansing in the past 3 months;
- Use antibiotics, probiotics (eg Yakult, Vifit, Activia) or specific prebiotics supplements 3 weeks prior to the start of the intervention
- Use of vitamin/mineral supplements 1 week prior to the start of the intervention (except for vitamin D and/or calcium)
- Use Methotrexate drugs or chronic use of antacids, H2 or proton-pump inhibitors
- With a history of GI disorders or GI surgery that are likely to interfere with the pH-dependent mode of action of the Colovit-capsule
- Patients with a pouch or stoma
- Pregnant or breastfeeding (or foreseen pregnancy during dietary intervention period)
- Swallowing disorders, not able to tolerate oral food, or use of tube feeding (EEN)
- Previously proven anaphylactic reaction to foods included in the food boxes
- Previously diagnosed with Celiac Disease or following a gluten-free diet
- Following a vegetarian or vegan diet
- Exclusion Criteria healthy subjects:
- Life expectancy \<12 months
- Previously diagnosed with IBD or any other chronic inflammatory condition
- Colonoscopy and colon cleansing in the past 3 months;
- Use antibiotics, probiotics (eg Yakult, Vifit, Activia) or specific prebiotics supplements 3 weeks prior to the start of the intervention
- Use of vitamin/mineral supplements 1 week prior to the start of the intervention (except for vitamin D and/or calcium)
- With a history of GI disorders or taken drugs that are likely to interfere with mode of action of interventions, such as chronic use of antacids or proton-pump inhibitors
- Abnormal clinical chemistry and haematology laboratory test results of clinical significance that in the judgment of the investigator would interfere with the participant's ability to comply with the study protocol (which might confound the interpretation of the study results), or put the participant at undue risk.
- Presence of a stoma
- History or presence of cancer in the prior two years, except for non-melanoma skin cancer.
- Recent history of (within 12 months of screening visit) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as \>60g (men) / 40g (women) pure alcohol per day (1.5 l / 1 l beer resp. 0.75 l / 0.5 l wine).
- Pregnant or breastfeeding (or foreseen pregnancy during dietary intervention period) The method of contraception must be recorded in the source documentation.
- Swallowing disorders, not able to tolerate oral food, or use of tube feeding (EEN)
- Previously proven anaphylactic reaction to foods included in the food boxes
- Previously diagnosed with Celiac Disease or following a gluten-free diet
- Following a vegetarian or vegan diet
Exclusion
Key Trial Info
Start Date :
October 8 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
510 Patients enrolled
Trial Details
Trial ID
NCT04913467
Start Date
October 8 2021
End Date
July 1 2025
Last Update
February 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Center Groningen
Groningen, Netherlands, 9713GZ